|
|
||||||||
Clinica di Malattie dell' Apparato Respiratorio and Istituto di Radiologia Medica, Istituo di Recovero e Cura a Carattere Scientifico, 27100 Pavia, Italy; Servizio di Fisiopatologia Respiratoria, Azienda Ospedaliera S. Croce e Carle, 12100 Cuneo, Italy; Laboratorium voor Pneumologie, Universitaire Ziekenhuis Gasthuisberg, B-3000 Leuven, Belgium; and Cattedra di Fisiopatologia Respiratoria, Dipartimento di Scienze Motorie e Riabilitative, Università di Genova, 16132 Genoa, Italy
We hypothesized that an altered effect of lung inflation on airway caliber may in part explain the isolated volume response to bronchodilators, i.e., an increase of forced vital capacity (FVC) without change in 1-s forced expiratory volume (FEV1). Small-airway caliber was measured by high-resolution computed tomography at functional residual capacity and total lung capacity in five chronic obstructive pulmonary disease patients with an isolated increase of FVC (FVC responders) and five with an increase of both FVC and FEV1 (FVC-FEV1 responders) after inhalation of salbutamol. In FVC-FEV1 responders, the airway diameter increased with the cube root of increase in lung volume but was unchanged or even decreased in four of five FVC responders. FVC responders had more severe emphysema, as inferred from lung function and imaging studies, than FVC-FEV1 responders. We speculate that longitudinal traction or space competition (Verbeken EK, Cauberghs M, and Van de Woestijne KP, J Appl Physiol 81: 2468-2480, 1996) are possible underlying mechanisms. We conclude that the isolated volume response to bronchodilators is associated with severe emphysema and likely results from an altered effect of lung inflation on airway caliber.
pulmonary emphysema; airway reversibility; 1-s forced expiratory volume; forced vital capacity; high-resolution computed tomography; chronic obstructive pulmonary disease
This article has been cited by other articles:
![]() |
M. Cazzola, W. MacNee, F. J. Martinez, K. F. Rabe, L. G. Franciosi, P. J. Barnes, V. Brusasco, P. S. Burge, P. M. A. Calverley, B. R. Celli, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur. Respir. J., February 1, 2008; 31(2): 416 - 469. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Pellegrino, G. Viegi, V. Brusasco, R. O. Crapo, F. Burgos, R. Casaburi, A. Coates, C. P. M. van der Grinten, P. Gustafsson, J. Hankinson, et al. Interpretative strategies for lung function tests Eur. Respir. J., November 1, 2005; 26(5): 948 - 968. [Full Text] [PDF] |
||||
![]() |
I. Cerveri, R. Dore, A. Corsico, M. C. Zoia, R. Pellegrino, V. Brusasco, and E. Pozzi Assessment of Emphysema in COPD: A Functional and Radiologic Study Chest, May 1, 2004; 125(5): 1714 - 1718. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Corsico, M. Milanese, S. Baraldo, G. L. Casoni, A. Papi, A. M. Riccio, I. Cerveri, M. Saetta, and V. Brusasco Small airway morphology and lung function in the transition from normality to chronic airway obstruction J Appl Physiol, July 1, 2003; 95(1): 441 - 447. [Abstract] [Full Text] [PDF] |
||||
![]() |
R.O. Crapo, R.L. Jensen, and F.E. Hargreave Airway inflammation in COPD: physiological outcome measures and induced sputum Eur. Respir. J., June 1, 2003; 21(41_suppl): 19S - 28s. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |